Analysing the influence of dapagliflozin on urinary tract infection vulnerability and kidney injury in mice infected with uropathogenic <scp> <i>Escherichia coli</i> </scp>
Dapagliflozin does not consistently influence UTI susceptibility and shows limited impact on kidney injury or fibrosis, suggesting SGLT2 inhibitors have minimal effects on UTI-related kidney complications.
Authors
- Sarah C. Linn (ORCID: https://orcid.org/0000-0003-4337-2966)
- Preeti R. John (ORCID: https://orcid.org/0000-0003-1772-0760)
- Aaron Simoni (ORCID: https://orcid.org/0000-0002-0657-3737)
- John David Spencer (ORCID: https://orcid.org/0000-0001-5509-7135)
- Juan de Dios Ruiz‐Rosado (ORCID: https://orcid.org/0000-0002-6429-9086)
- Laura Schwartz (ORCID: https://orcid.org/0000-0002-4056-3030)
- Brian Becknell (ORCID: https://orcid.org/0000-0002-2750-4415)
- Kristin Salamon
Institutions
- Nationwide Children's Hospital (US)
- The Ohio State University (US)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1111/dom.15981
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases